Trial of Oral Valproic Acid for Retinitis Pigmentosa

Phase 2

Completed

• Conditions: Retinitis Pigmentosa
• Interventions: Drug: Placebo; Drug: Valproic Acid

• Registration Number: NCT01233609
• Lead Sponsor: Foundation Fighting Blindness

Brief Summary

The objectives of this study are to evaluate the efficacy of Valproic Acid (VPA) to both slow the progression of visual function loss and/or to restore visual function in patients with Autosomal Dominant Retinitis Pigmentosa (RP) and to collect safety and tolerability information.

Detailed Description

Retinitis Pigmentosa (RP) is an incurable and untreatable group of heterogeneous retinal degenerative diseases that cause severe visual loss. There is currently no therapeutic that substantially slows the progression of this disease, and certainly none that can restore vision in RP patients. The Valproic Acid (VPA) study is designed as a six-site, interventional, prospective, randomized, placebo controlled, double-blinded study of 90 participants to evaluate the efficacy of oral Valproic Acid to both slow the progression of visual function loss and/or to restore visual function in patients with an Autosomal Dominant RP genetic mutation and to collect safety and tolerability information. Patients that participate in the study will be randomized to either placebo or VPA in a 1:1 ratio.

Study Timeline

• Study Start: 2010-11
• Study First Submitted: 2010-11-01
• Study First Submitted QC: 2010-11-02
• Study First Posted: 2010-11-03
• Primary Completion: 2015-12
• Study Completion: 2015-12
• Results First Submitted: 2017-08-17
• Status Verified: 2017-10
• Results First Submitted QC: 2017-10-24
• Last Update Submitted: 2017-10-24
• Results First Posted: 2017-12-02
• Last Update Posted: 2017-12-02

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 90

Inclusion Criteria

1. Understand/sign the IRB-approved study informed consent document.
2. Age greater than or equal to 18 years, no upper age limit
3. Males and non-child bearing females must weigh ≥40 Kg and ≤158.9 Kg; Females of child bearing potential must weigh ≥40 Kg and ≤74.9 Kg.
4. Diagnosis of Retinitis Pigmentosa (RP).
5. Visual acuity of greater than or equal to 35 letters in at least one eye as measured by the EVA-ETDRS (equivalent to 20/200 on a Snellen chart).
6. Genotyped as autosomal dominant form of RP.
7. Female subjects of childbearing potential and male subjects able to father children must have (or have a partner who has) had a hysterectomy or vasectomy, be completely abstinent from intercourse or must commit to practice at least two acceptable methods of contraception to minimize the chance of pregnancy during the study and for the 13 week period after stopping the study drug.
8. Female subjects of childbearing potential must have a negative urine pregnancy test at study entry and throughout the duration of the study.
9. Willingness to comply with the protocol.

Read More

Exclusion Criteria

1. Medical problems that make consistent follow-up over the treatment period unlikely (e.g. stroke, severe MI, end stage malignancy), or in general a poor medical risk because of other systemic diseases or active uncontrolled infections.
2. Other retinal diseases: Glaucoma, retinal inflammatory disease (CME is allowable), cataract worse than +2 NS, or herpes simplex virus of the eye.
3. Intact visual field of 5⁰ or less.
4. Subject unable to provide reliable perimetry measurements in both eyes for both static and kinetic visual field, as determined by the Reading Center.
5. Diabetes.
6. History of cancer (other than non-melanoma skin cancer) diagnosed, or requiring treatment within the past 2 years.
7. A hemoglobin concentration, a platelet count or an absolute neutrophil count below the lower limit of normal at study entry.
8. Suspected liver dysfunction determined by having liver function values elevated above the upper limit of normal.
9. History of pancreatitis by clinical features and/or laboratory abnormalities in the last 12 months.
10. Renal dysfunction based on serum creatinine,(MDRD) equation.
11. Urea cycle disorders.
12. History of neurological conditions including epilepsy, history of brain injury, encephalitis, or any organic brain syndrome.
13. History of schizophrenia, schizoaffective disorder, bipolar disorder, suicidality or organic mental disorders.
14. Currently receiving valproic acid or other anti-convulsants.
15. Sensitive to or have ever had an allergic reaction to valproic Acid.
16. Sensitive to or have ever had an allergic reaction to peanuts as peanut oil is an inactive ingredient in valproic acid capsules and the placebo.
17. Has taken one of the disallowed drugs at least 2 weeks prior to randomization.
18. Pregnant women.
19. Lactating mothers who are breast feeding their babies.
20. RP patients involved in other clinical trials within the last 3 months.
21. Require enrollment by consent of a legally authorized representative.
22. Persons who are unable to read are not allowed to consent for themselves or others to participate in this study.
23. The potential participant lives in the same household as a current participant in this protocol.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	Subjects who receive placebo
Valproic Acid	Valproic Acid	Subjects who receive valproic acid

Primary Outcome Measures

Name	Time	Method
Mean Change in Visual Field Area From Baseline to 52 Weeks--III4e Isopter	baseline to week 52	Mean change in visual field area from baseline to 52 weeks. Visual field area is measured with semi-automated kinetic perimetry (SKP) using the Octopus 900 (Haag-Streit) with the III4e target size for each eye and done at least twice to ensure reliable sessions; the visual field area measurements are averaged over the two sessions. Analysis performed with linear mixed model

Secondary Outcome Measures

Name	Time	Method
Mean Change in Visual Field Area From Baseline to 52 Weeks--I4e Isopter	baseline to week 52	Mean change in visual field area from baseline to 52 weeks. Visual field area is measured with semi-automated kinetic perimetry (SKP) using the Octopus 900 (Haag-Streit) with the I4e target size for each eye and done at least twice to ensure reliable sessions; the visual field area measurements are averaged over the two sessions. Analysis performed with linear mixed model
Static Perimetry by Treatment Arm--Full Field Hill of Vision	baseline to week 52	Mean change from baseline at week 52 for Full field Hill of Vision (Static perimetry)
Static Perimetry Volume--30 Degree Hill of Vision	baseline to week 52	Mean Change from baseline to week 52 for Static Perimetry Volume --30 Degree Hill of Vision. Full field static perimetry protocol was followed using the Octopus 900 (Haag-Streit) for a single session for each eye.
Mean Change From Baseline in Best Corrected Visual Acuity	baseline to week 52	Mean change in best corrected visual acuity as assessed by ETDRS (Early Treatment Diabetic Retinopathy Study) method from baseline to week 52

Trial Locations

Locations (6)

University of Utah School of Medicine, Moran Eye Center; 🇺🇸 Salt Lake City, Utah, United States

University of Tennessee, Hamilton Eye Institute; 🇺🇸 Memphis, Tennessee, United States

Retina Foundation of the Southwest; 🇺🇸 Dallas, Texas, United States

University of Michigan, Ann Arbor; 🇺🇸 Ann Arbor, Michigan, United States

University of Miami, Bascom Palmer Eye Institute; 🇺🇸 Miami, Florida, United States

Oregon Health & Science University; 🇺🇸 Portland, Oregon, United States